A 12 month, partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal antibody, CFZ533, in de novo and maintenance kidney transplant recipients
A phase III, randomized, double-blind, active comparator-controlled study to evaluate the efficacy and safety of MK-8228 (Letermovir) versus valganciclovir for the prevention of human cytomegalovirus (CMV) disease in adult kidney transplant recipients
A phase IV prospective study, non-randomized, multi-center, multi-national, open-label cohort to assess thrombotic microangiopathy (TMA) disease manifestation in patients with atypical hemolytic uremic syndrome (aHUS) participating in the M11-001 aHUS Registry
A phase II, uncontrolled, two-stage, dose-escalation cohort study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and clinical activity of OMS721 in adults with thrombotic microangiopathies
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and clinical diagnosis of diabetic kidney disease in addition to standard of care
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
A Randomized, double-blind, active-controlled study to evaluate the safety and efficacity of CCX168 (avacopan) in patients with anti-neutrophil cytoplasmic antibody (anca-associated vaculitis treated concomitantly with rituximab or cyclophosphamide / azathioprine.
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal transplant efficacy and safety outcomes with an everolimus-based regimen (TRANSFORM)